Laurence Nore is a seasoned US Business Advisor at Inatherys, a pioneering clinical-stage biotech company dedicated to developing innovative anti-CD71 targeted therapies for acute myeloid leukemia (AML) and solid tumors. With a career spanning over two decades in the biotech sector, Laurence has honed his...
Laurence Nore is a seasoned US Business Advisor at Inatherys, a pioneering clinical-stage biotech company dedicated to developing innovative anti-CD71 targeted therapies for acute myeloid leukemia (AML) and solid tumors. With a career spanning over two decades in the biotech sector, Laurence has honed his expertise in corporate development, business strategy, and negotiations, making him an invaluable asset to the Inatherys team. His journey began three decades ago, inspired by a personal connection to Cystic Fibrosis, which catalyzed his transition from banking in France to the dynamic world of biotechnology in the United States.
At Inatherys, Laurence plays a crucial role in supporting the CEO's efforts to forge strategic partnerships in the US market. His deep understanding of the biotech landscape, coupled with his skills in fundraising and contract negotiation, enables him to identify and cultivate relationships with potential collaborators and investors. Laurence's strategic vision is instrumental in navigating the complexities of market planning, particularly in the context of developing novel therapies that address unmet medical needs in oncology.
In addition to his corporate development expertise, Laurence's background in molecular diagnostics and infectious diseases enriches his approach to business strategy, allowing him to leverage cross-disciplinary insights that drive innovation. As Inatherys continues to advance its groundbreaking therapies, Laurence remains committed to fostering collaborations that will accelerate the company's growth and ultimately improve patient outcomes in the fight against cancer. His passion for the biotech industry, combined with his extensive experience, positions him as a key player in shaping the future of targeted therapies.
